Merck’s Bravecto (Fluralaner) Receives Positive Opinion from EMA’s CVMP to Protect Dogs Against Ticks and Fleas
Shots:
- The CVMP adopted a positive opinion for the injectable formulation of Bravecto (50 mg/ml powder & solvent for suspension for injection) for dogs and puppies of 6 mos. of age and older
- Once approved, this injectable Bravecto becomes the first and only once-yearly solution for flea and tick medication, and persistent killing of fleas and ticks in dogs, including protection against various species for 12 mos.
- The market authorization for Bravecto in the EU is currently pending, and the decision is expected to be announced in Q1’24
Ref: Merck | Image: Merck
Related News:- Merck Animal Health’s Bravecto Receives the US FDA’s Approval to Treat Asian Long-Horned Ticks in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
